One-Year Results of the Multilayer Flow Modulator Stent in the Management of Thoracoabdominal Aortic Aneurysms and Type B Dissections

Abstract

MFM implantation instigates a process of aortic remodeling involving initial thrombus deposition, which slowed between 6 and 12 months. Increasing sac size did not herald rupture, and the MFM was not associated with loss of native side branches. With physiological modulation of the aneurysm, the MFM offers promise for resolution of complex thoracoabdominal pathology with off-the-shelf availability, but this disruptive technology requires further development and technical refinement. Long-term follow-up of the registry patients is mandatory before establishing a randomized controlled study.

Endovascular repair of the ascending aorta in patients at high risk for open repair

“…Maintaining coronary perfusion might involve disruptive technology, such as a multilayer flow modulator, for endovascular treatment to be applied to the aortic root. 15 Finally, appropriate patient selection in the management of ascending aortic pathologies remains of utmost importance. We must be aware that an open surgical approach remains the criterion standard, yielding excellent contemporary results.…”

Finite Element Modeling of A Novel Self-Expanding Endovascular Stent Method in Treatment of Aortic Aneurysms

“…Femoral arteriotomy for vascular access by a surgeon would be frequently required in these patients before deployment. Flow exclusion by a multilayered nitinol model is another method of treatment of aneurysms and dissections of aorta1112. We investigated a simple self-expanding Nitinol stent in the treatment of aortic aneurysms, and its effect on the aneurysm and aortic wall stress parameters.…”

Assessment of Biocompatibility of the Multilayer Flow Modulator with Differing Thread Designs

“…Clinical results have been published on the MFM device used to treat aortic, peripheral and visceral aneurysms [7][8][9][15][16][17]. However, there is paucity of long-term data in relation to this new device, with current literature reporting relatively short follow up results [15][16][17].…”

“…However, there is paucity of long-term data in relation to this new device, with current literature reporting relatively short follow up results [15][16][17]. When conducted strictly in accordance with the device instructions for use (IFU), deployment of the MFM has produced consistently positive outcomes in aortic pathologies including TAAA and aortic type B dissections [7][8][9]15]. The preliminary results of this study compare favorably with the current clinical findings, given the evidence for endothelialization and integration of the device into the artery.…”

“…The device has since been implanted in numerous patients on compassionate grounds [4][5][6][7][8]. The MFM has been used successfully to treat renal artery aneurysms [4,5], visceral artery aneurysms [6], and aortic pathologies including TAAA and aortic type B dissections [3,[7][8][9].…”